MS-Leaders Home


Click here to Register



Remember Me \| Forgot Password \| Send to a Colleague

Clinical Dialogue
& eCase Challenge

MS-Journal Club

Ask The Experts

MS-Leaders.org™ is an online educational resource for MS treating clinicians designed to provide cutting edge information and resources to help support patient care. MS-Leaders.org provides a variety of engaging and clinically relevant educational platforms to deliver a breadth of content to meet the needs of busy clinicians...

[X] Close

About MS-Leaders

Clinical Dialogues and eCase Challenges: Clinical Dialogues are video-based moderated discussions featuring leading MS experts. Clinical Dialogues are accompanied by an interactive eCase Challenge, which presents challenging case scenarios and supports the application of the education delivered in the Clinical Dialogue program into clinical practice. Following each case, a video commentary provides key clinical pearls that summarize the most important aspects of the case.
Ask the Expert: Ask the Expert provides MS-Leaders.org registrants with the opportunity to present their own clinical challenges to leading MS experts, and to review a growing library of archived questions and answers. Responses to questions are sent directly to the registrant posing the question, thus providing a unique opportunity for MS treating clinicians to readily access leading MS experts.

We encourage you to register with MS-Leaders.org today and to take advantage of the many resources that this unique online educational site offers.

MS-Leaders.org™ is a trademark of Medical Logix, LLC.

MS-Leaders Advisors

J. Theodore Phillips, MD, PhD

Michael K. Racke, MD

Timothy Vollmer, MD

It is estimated that 3-10% of individuals with MS develop symptoms in childhood and adolescence. Diagnosing pediatric MS can be difficult due to the rarity of the disease in this age group and the existence of a broad array of disease mimics. Diagnosis may also be delayed due to a lack of recognition or dismissal of symptoms early in the course of the disease. The recent FDA licensure of fingolimod as the first agent to treat pediatric MS is a significant event for the field, highlighting a growing recognition of pediatric-onset MS and the need for efficacy and safety data on DMTs used in children.

The University of Texas Southwestern Medical Center designates this enduring material for a maximum of 1.75 AMA PRA Category Credits™

CLICK HERE to view this program

In April 2018, the American Academy of Neurology (AAN) issued a new practice guideline on the use of disease-modifying therapies (DMTs) in adults with MS. Included in this document are recommendations concerning when and how to switch DMTs. It is incumbent on MS-treating clinicians to be knowledgeable about these recommendations and be prepared to implement them in clinical practice. This program is designed to address these recent recommendations and to facilitate their timely incorporation into clinical practice.

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category Credits™

CLICK HERE to view this program.